This is because we are comparing a standard of care that has been established with a minimum of 1 clinical trial with an experimental drug about to be tested. So, where is the claimed "equipoise ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

A seminal paper by Miller and Brody [1] clearly laid the general framework on why we should abandon the term "clinical equipoise" in research. Their paper argued that the concept of equipoise ...

a clinical research consultant and a research ethicist at Equipoise Consulting. "This wasn't just kind of an effort to be woke," says McNair. "This wasn't just diversity for the sake of political ...